← ALNYLAM PHARMACEUTICALS, INC. ALNY
Market Price
$228.54
Market Cap
$30.32B
P/E Ratio
98.09
Revenue (FY 2025)
↑65.2% YoY
$3.71B
3-Yr CAGR: 53.0%
Net Income
↑212.8% YoY
$313.75M
Net Margin: 8.4%
Free Cash Flow
↑1,192.7% YoY
$465.38M
FCF Yield: 1.53%
EPS (Diluted)
↑206.9% YoY
$2.33
Basic: $2.39
Return on Equity
Efficiency
39.8%
ROA: 111.3%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ALNY)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2017: Revenue YoY (+90.7%) is identical to Gross Profit YoY (+90.7%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $47.2M | — | $40.4M | $-410.1M | — | $-4.79 | — | $-307.7M | $-372.3M | — |
| FY 2017 | $89.9M | +90.7% | $77.0M | $-490.9M | -19.7% | $-5.42 | -13.2% | $-382.8M | $-487.0M | -30.8% |
| FY 2018 | $74.9M | -16.7% | $73.1M | $-761.5M | -55.1% | $-7.57 | -39.7% | $-562.6M | $-689.5M | -41.6% |
| FY 2019 | $219.8M | +193.4% | $194.7M | $-886.1M | -16.4% | $-8.11 | -7.1% | $-278.4M | $-418.6M | +39.3% |
| FY 2020 | $492.9M | +124.3% | $408.4M | $-858.3M | +3.1% | $-7.46 | +8.0% | $-615.0M | $-685.3M | -63.7% |
| FY 2021 | $844.3M | +71.3% | $701.3M | $-852.8M | +0.6% | $-7.20 | +3.5% | $-641.7M | $-718.1M | -4.8% |
| FY 2022 | $1,037.4M | +22.9% | $881.5M | $-1,131.2M | -32.6% | $-9.30 | -29.2% | $-541.3M | $-613.3M | +14.6% |
| FY 2023 | $1,828.3M | +76.2% | $1,560.1M | $-440.2M | +61.1% | $-3.52 | +62.2% | $104.2M | $41.9M | +106.8% |
| FY 2024 | $2,248.2M | +23.0% | $1,941.7M | $-278.2M | +36.8% | $-2.18 | +38.1% | $-8.3M | $-42.6M | -201.5% |
| FY 2025 | $3,713.9M | +65.2% | $3,036.8M | $313.7M | +212.8% | $2.33 | +206.9% | $524.1M | $465.4M | +1,192.7% |
Valuation
Market Price
$228.54
Market Cap
$30.32B
Enterprise Value
N/A
P/E Ratio
98.09
P/B Ratio
38.67
FCF Yield
1.53%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
81.77%
Operating Margin
13.51%
Net Margin
8.45%
Return on Equity (ROE)
39.76%
Return on Assets (ROA)
111.30%
Asset Turnover
13.18x
Revenue 3-Yr CAGR
52.98%
Financial Health & Liquidity
Current Ratio
0.26
Cash Ratio
1.53
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$1.66B
Total Debt
N/A
Book Value / Share
$5.91
Cash Flow Efficiency
Operating Cash Flow
$524.08M
Capital Expenditures (CapEx)
$58.70M
Free Cash Flow
$465.38M
OCF / Revenue
14.11%
FCF / Revenue
12.53%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$2.33
EPS (Basic)
$2.39
Dividends / Share
N/A
Book Value / Share
$5.91
EPS YoY Growth
206.88%
Balance Sheet (FY 2025)
Total Assets
$281.89M
Total Liabilities
$1.08B
Stockholders' Equity
$789.18M
Current Assets
$281.89M
Current Liabilities
$1.08B